EAM Investors LLC Buys 18,446 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

EAM Investors LLC lifted its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 56.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,183 shares of the company's stock after purchasing an additional 18,446 shares during the quarter. EAM Investors LLC owned 0.19% of GeneDx worth $3,934,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. MCF Advisors LLC boosted its holdings in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock worth $27,000 after purchasing an additional 182 shares during the last quarter. Sterling Capital Management LLC lifted its stake in GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after purchasing an additional 316 shares during the last quarter. Global Retirement Partners LLC acquired a new position in GeneDx during the fourth quarter worth approximately $28,000. KLP Kapitalforvaltning AS bought a new stake in GeneDx in the fourth quarter valued at approximately $200,000. Finally, Evolution Wealth Advisors LLC bought a new position in GeneDx during the fourth quarter worth $202,000. 61.72% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. TD Cowen upped their target price on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. The Goldman Sachs Group lifted their target price on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, GeneDx presently has a consensus rating of "Moderate Buy" and an average price target of $72.33.

GeneDx Price Performance

Shares of NASDAQ WGS traded down $6.63 during mid-day trading on Monday, hitting $88.84. 311,793 shares of the stock traded hands, compared to its average volume of 683,603. The firm has a 50 day simple moving average of $93.79 and a two-hundred day simple moving average of $80.27. GeneDx Holdings Corp. has a twelve month low of $9.60 and a twelve month high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a market cap of $2.49 billion, a PE ratio of -45.33 and a beta of 1.93.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Insider Transactions at GeneDx

In related news, CFO Kevin Feeley sold 15,516 shares of GeneDx stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $92.18, for a total value of $1,430,264.88. Following the sale, the chief financial officer now owns 1,726 shares of the company's stock, valued at approximately $159,102.68. The trade was a 89.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of GeneDx stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $130,041.36. Following the completion of the sale, the chief executive officer now directly owns 3,937 shares of the company's stock, valued at approximately $308,975.76. This trade represents a 29.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 138,780 shares of company stock valued at $12,907,437 over the last ninety days. 27.30% of the stock is owned by company insiders.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.